1. Tumor Mutational Burden, Neoantigens, and a Pathway to Predicting Response to Checkpoint Inhibitors

2. Current Status of Biomarkers for Immune Checkpoint Inhibitors

3. Experience With PD-L1 Where Do We Stand?

4. What About MSI as a Biomarker?

5. MSI-H and Response to Immunotherapy

6. Novel Predictive Biomarker TMB

7. Tumor Mutational Burden

8. Measuring TMB

9. Tumor-Based vs Blood-Based TMB Assessment

10. TMB in NSCLC CheckMate-012

11. TMB in SCLC CheckMate-032

12. TMB and Lung Cancer Phase 3 CheckMate-227 Study Design

13. CheckMate-227 TMB Predicts for Benefit From Combination Immunotherapy in NSCLC

14. CheckMate-227 TMB Predicts for Benefit From Combination Immunotherapy in NSCLC (cont)

15. Defining the Threshold for TMB CheckMate 568

16. TMB as a Biomarker in the Phase 3 MYSTIC Trial Study Design

17. MYSTIC Trial OS According to Blood TMB

18. MYSTIC Trial OS According to Tumor TMB

19. Different Assays for Blood-Based TMB Testing

20. Considerations for Blood-Based TMB Testing

21. Potential to Combine Immunotherapy Biomarkers

22. Conclusions

23. Abbreviations

24. Abbreviations (cont)